The characteristics and outcomes of parainfluenza virus infections in 200 patients with leukemia or recipients of hematopoietic stem cell transplantation

Abstract

Continuing Medical Education onlineThis activity has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education through the joint sponsorship of Medscape, LLC and the American Society of Hematology. Medscape, LLC is accredited by the ACCME to provide continuing medical education for physicians. Medscape, LLC designates this Journal-based CME activity for a maximum of 1.0 AMA PRA Category 1 Credit(s) ™ . Physicians should claim only the credit commensurate with the extent of their participation in the activity. All other clinicians completing this activity will be issued a certificate of participation. To participate in this journal CME activity: (1) review the learning objectives and author disclosures; (2) study the education content; (3) take the post-test with a 70% minimum passing score and complete the evaluation at http://www.medscape.org/journal/blood; and (4) view/print certificate. For CME questions, see page 2969. Disclosures The authors, the Associate Editor Martin S. Tallman, and CME questions author Laurie Barclay, freelance writer and reviewer, Medscape, LLC, declare no competing financial interests. Learning objectives Upon completion of this activity, participants will be able to:1. Describe the prevalence and clinical characteristics of parainfluenza virus (PIV) infections in patients with leukemia or HSCT, based on a medical record review.2. Describe outcomes of PIV infections in patients with leukemia or HSCT and the factors predicting progression to pneumonia, based on a medical record review.3. Describe risk factors for mortality from PIV infections in patients with leukemia or HSCT, based on a medical record review.

Oral ribavirin for treatment of respiratory syncitial virus and parainfluenza 3 virus infections post allogeneic haematopoietic stem cell transplantation

“…[1][2][3][4]8,12,[14][15][16][17][18][19][20][21] Furthermore, the development of LRTI has been consistently associated with significantly higher risk of death. 12,13,17,18 Early intervention with antiviral therapy has been demonstrated to reduce the risk of progression to pneumonia 7 and may lead to improved survival. 22 The importance of commencing RBV early is highlighted by the lower response to RBV once PIV3 viral infection is well established.…”

Parainfluenza virus type 3 Ab in allogeneic hematopoietic cell transplant recipients: factors influencing post-transplant Ab titers and associated outcomes

“…7–13 Historically, risk factors for PIV LRD include lymphopenia, high dose corticosteroid use, myeloablative conditioning, infection early after HCT, and respiratory co-pathogens. 9–11, 14, 15 …”

Epidemiology and clinical outcome of lower respiratory tract infections by respiratory syncytial virus or parainfluenza virus type 3 in adults receiving treatment for either acute leukemia or severe aplastic anemia: a retrospective single center study

“…Limited information is reported on epidemiology and clinical impact of LRTID associated with either RSV or PIV in neutropenic patients with either acute leukemia (AL) or aplastic anemia (AA), who are not undergoing HSCT [6][7][8][9]. We have retrospectively analyzed the incidence of lung infiltrates and, subsequently, the frequency of detection of either RSV or PIV type-3 (PIV3) antigens on bronchoalveolar lavage (BAL) samples in 144 adults (median age 59 years, range 15-80), observed at our institution over a period of 5 years (2010-2014), with either AL under intensive chemotherapy or severe AA receiving immunosuppressive treatment (Table 1).…”

“…In our series of neutropenic individuals with either RSV-or PIV3-associated LRTID, a non-severe clinical behavior, with adequate antiviral therapy and in the absence of either co-infections or comorbidities, was observed. Prospective studies are warranted to further investigate precise incidence, best therapeutic approach and clinical outcome of RSV-or PIV3-associated respiratory infections in adults with either AL or AA [1,3,9]. …”